How to use FDA drug approval documents for evidence syntheses

BMJ (Online)

Volumn 362, Issue , 2018, Pages

  Ladanie, Aviv ^a,b   Ewald, Hannah ^a,b,c   Kasenda, Benjamin ^a,d   Hemkens, Lars G ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG LABELING; DRUG SCREENING; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; IMMUNOGENICITY; INFORMATION PROCESSING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RISK BENEFIT ANALYSIS; SYSTEMATIC ERROR; CLINICAL TRIAL (TOPIC); HUMAN; META ANALYSIS (TOPIC); METHODOLOGY; PUBLISHING; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; META-ANALYSIS AS TOPIC; PUBLICATION BIAS; PUBLICATIONS; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85049850153     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.k2815     Document Type: Article

References (32)

1. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60. doi:10.1056/NEJMsa065779
2. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008;5:e217, discussion e217. doi:10.1371/journal.pmed.0050217
3. Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med 2008;5:e191. doi:10.1371/journal.pmed.0050191
4. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ 2012;344:d7202. doi:10.1136/bmj.d7202
5. Man-Son-Hing M, Wells G, Lau A. Quinine for nocturnal leg cramps: a meta-analysis including unpublished data. J Gen Intern Med 1998;13:600-6. doi:10.1046/j.1525-1497.1998.00182.x
6. McDonagh MS, Peterson K, Balshem H, Helfand M. US Food and Drug Administration documents can provide unpublished evidence relevant to systematic reviews. J Clin Epidemiol 2013;66:1071-81. doi:10.1016/j.jclinepi.2013.05.006
7. MacLean CH, Morton SC, Ofman JJ, Roth EA, Shekelle PG, Southern California Evidence-Based Practice Center. How useful are unpublished data from the Food and Drug Administration in metaanalysis? J Clin Epidemiol 2003;56:44-51. doi:10.1016/S0895-4356(02)00520-6
8. Halfpenny NJA, Quigley JM, Thompson JC, Scott DA. Value and usability of unpublished data sources for systematic reviews and network meta-analyses. Evid Based Med 2016;21:208-13. doi:10.1136/ebmed-2016-110494
9. OpenTrialsFDA. OpenTrialsFDA: an interview with Erick Turner. Secondary OpenTrialsFDA: an interview with Erick Turner 2016. https://opentrials.net/2016/10/05/opentrialsfda-an-interview-witherick-turner/.
10. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ 2013;346:f2231. doi:10.1136/bmj.f2231
11. Golder S, Loke YK, Wright K, Sterrantino C. Most systematic reviews of adverse effects did not include unpublished data. J Clin Epidemiol 2016;77:125-33. doi:10.1016/j.jclinepi.2016.05.003
12. O'Connor AB. The need for improved access to FDA reviews. JAMA 2009;302:191-3. doi:10.1001/jama.2009.973
13. Turner EH. How to access and process FDA drug approval packages for use in research. BMJ 2013;347:f5992. doi:10.1136/bmj.f5992
14. Wolfe N, Gøtzsche PC, Bero L. Strategies for obtaining unpublished drug trial data: a qualitative interview study. Syst Rev 2013;2:31. doi:10.1186/2046-4053-2-31
15. Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. J Clin Epidemiol 2015;68:102-7. doi:10.1016/j.jclinepi.2014.06.019
16. Goldacre B, Turner EOpenTrials team. You can now search FDA approval documents easily at fda.opentrials.net. BMJ 2017;356:j677. doi:10.1136/bmj.j677
17. Papathanasiou P, Brassart L, Blake P, et al. Transparency in drug regulation: public assessment reports in Europe and Australia. Drug Discov Today 2016;21:1806-13. doi:10.1016/j.drudis.2016.06.025
18. The Cochrane Collaboration. What's new in the Cochrane Handbook? Secondary What's new in the Cochrane Handbook? http://training. cochrane.org/whats-new-cochrane-handbook.
19. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.
20. Institute of Medicine (IOM). Data gathered as part of the FDA approval process. The National Academies Press, 2011.
21. US Food and Drug Administration. Drugs@FDA database. Secondary Drugs@FDA database. www.fda.gov/drugsatfda.
22. US Food and Drug Administration. Search for FDA guidance documents. Secondary Search for FDA guidance documents. www. fda.gov/RegulatoryInformation/Guidances/default.htm.
23. US Food and Drug Administration. Manual of policies & procedures (CDER). Secondary Manual of policies & procedures (CDER). www.fda. gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/default.htm.
24. US Food and Drug Administration. Good Review Practices (GRPs). Secondary Good Review Practices (GRPs). www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ucm118777.htm.
25. US Food and Drug Administration. Drugs@FDA frequently asked questions. What drug products are in Drugs@FDA? www.accessdata. fda.gov/scripts/cder/daf/index.cfm?event=faq.page#contains.
26. US Food and Drug Administration. Drug approval package: Trelstar depot (triptorelin pamoate) injection (Application No 20-715). www. accessdata.fda.gov/drugsatfda-docs/nda/2000/20-715-Trelstar.cfm.
27. US Food and Drug Administration. Drug approval package: Stelara (ustekinumab) injection (Application No 125261s0000). www. accessdata.fda.gov/drugsatfda-docs/nda/2009/125261s000TOC. cfm.
28. US Food and Drug Administration. Drug approval package: Perjeta (pertuzumab) (Application No 125409). www.accessdata.fda.gov/drugsatfda-docs/nda/2013/125409-perjeta-toc.cfm.
29. US Food and Drug Administration. Good review practice: Statistical review template. 2012. www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/manualofpoliciesprocedures/ucm313814.pdf.
30. US Food and Drug Administration. Regulatory information: Freedom of information. 2018. www.fda.gov/RegulatoryInformation/FOI/default.htm.
31. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. doi:10.1186/1745-6215-8-16
32. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34. doi:10.1002/(SICI)1097-0258(19981230)17:242815::AID-SIM1103.0.CO;2-8